Symbols

XTLB

Xtl Biopharmaceuticals·NASDAQ

--(--)

7.91 / 10

Outperform

Fund‑flow score is 7.91/10 (good), with overall, block, small, large and extra‑large investors net inflowing; only medium investors show outflows. Analyst coverage is absent (ana_eval = -1). Strong liquidity contrasts with missing analyst guidance, urging caution despite positive cash flow.

Fund Flow Rating

Is money flowing into or out of XTLB?

XTLB holds a Neutral analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 7.91/10 (Outperform).